TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
Study Details
Study Description
Brief Summary
The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). The investigators confirmed that the combination therapy yielded better survival data than the combined administration of Atezolizumab/Bevacizumab and TACE (TACE-AB) in patients with advanced HCC and Type I/II PVTT (Based on Cheng's PVTT classification).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This is a multicenter, open-label trial, randomized controlled to evaluate the efficacy and safety of TACE-AB-I compared with TACE-AB for the treatment of HCC with branch PVTT. 234 HCC patients with branch PVTT will be enrolled in this study. The Patients will be treated with TACE-AB-I or TACE-AB using a 1:1 randomization scheme. TACE will be performed for the patients after randomization. Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) will be started at 3-7 days after the first TACE and I-125 Seeds Brachytherapy and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. For patients in the TACE-AB-I arm, iodion-125 seeds will be implanted into the PVTT (according to the pre-operative planning) under CT guidance within 3-7 days after the first TACE. TACE and iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: TACE plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy (TACE-AB-I) TACE will be performed for the patients after randomization. Iodion-125 seeds will be implanted into the PVTT under CT guidance within 3-7 days after the first TACE. Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) will be started at 3-7 days after the first TACE and I-125 Seeds Brachytherapy. TACE and iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination. |
Procedure: I-125 Seeds Brachytherapy in PVTT
Iodine125 seed implantation into the PVTT was conducted 3-7 days after TACE when the results of the liver function tests were comparable to those obtained before TACE. Pre-procedural planning was conducted using a three-dimensional conformal radiation therapy treatment planning system (TPS) to determine the number of Iodine125 seeds required, the target location for implantation, the best percutaneous puncture site and the access route. The targeted zone for implantation was the tumour thrombosis in the segmental portal vein, left/right portal vein. Implantation was guided by CT, and the Iodine125 seeds were implanted into the PVTT using 18 G needles and the implantation gun that housed the Iodine125 seeds in the cartridge chamber.
Other Names:
Procedure: Transcatheter arterial chemoembolization
TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE).
Other Names:
Drug: Atezolizumab plus Bevacizumab
Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) .
Other Names:
|
| Active Comparator: TACE and Atezolizumab/Bevacizumab (TACE-AB) TACE will be performed for the patients after randomization. Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) will be started at 3-7 days after the first TACE. TACE can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination. |
Procedure: Transcatheter arterial chemoembolization
TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE).
Other Names:
Drug: Atezolizumab plus Bevacizumab
Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) .
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Overall survival (OS) [2 years]
Time from randomization to death from any cause.
Secondary Outcome Measures
- Progression free survival (PFS) [2 years]
Time from randomization to disease progression (mRECIST) or death from any cause, whichever occurred first.
- Objective response rate (ORR) [2 years]
The percentage of patients who had a best overall tumor response rating of CR and PR (mRECIST).
- Duration of portal patency [2 years]
The time from randomization until the date that complete portal vein occlusion was confirmed (if the portal vein is patent at diagnosis).
- Adverse events (AEs) [2 years]
Number of patients with AE, treatment-related AE (TRAE), AE of special interest (AESI), serious adverse event (SAE), assessed by NCI CTCAE v5.0.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age between18 and 75 years;
-
Has a diagnosis of HCC confirmed by radiology, histology, or cytology;
-
Type I PVTT or type II PVTT;
-
Child-Pugh class A;
-
Eastern Cooperative Group performance status (ECOG) score of 0-1;
-
No prior systemic therapy for HCC.
-
Adequate hematologic and end-organ function;
-
At least one measurable intrahepatic target lesion.
Exclusion Criteria:
-
Diffuse HCC;
-
Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular/cholangiocarcinoma subtypes (confirmed by histology, or pathology) are not eligible;
-
Evidence of extrahepatic spread (EHS);
-
Any condition representing a contraindication to TACE or I-125 seeds brachytherapy as determined by the investigators;
-
Evidence or history of bleeding diathesis or any hemorrhage or bleeding event >CTCAE grade 3 within 4 weeks prior to randomization;
-
Active or history of autoimmune disease or immune deficiency;
-
Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding;
-
A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment;
-
Evidence of bleeding diathesis or significant coagulopathy;
-
Pregnant or breastfeeding females;
-
Significant cardiovascular disease;
-
Severe infection, such as active tuberculosis;
-
Serious medical comorbidities;
-
History of organ or cells transplantation;
-
History of other uncurable malignancies.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Third Affiliated Hospital, Sun Yat-Sen University
- Sun Yat-sen University
- Fifth Affiliated Hospital, Sun Yat-Sen University
- Second Affiliated Hospital of Guangzhou Medical University
- Maoming People's Hospital
- Shandong Provincial Third Hospital
Investigators
- Principal Investigator: Mingsheng Huang, M.D. & Ph.D., Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- II2023-162-02